Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence

Journal of Clinical Psychiatry

Volumn 69, Issue 3, 2008, Pages 392-399

  Muhonen, Leea H ^a   Lönnqvist, Jouko ^a   Juva, Kati ^a   Alho, Hannu ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; MEMANTINE;

ADULT; AGED; AGGRESSIVENESS; ALCOHOLISM; ALZHEIMER DISEASE; ARTICLE; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISORIENTATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; ECZEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL INSTABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING; XEROSTOMIA;

EID: 42249095073     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0308     Document Type: Article

References (46)

1. Kessler RC, Crum RM, Warner LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997;54:313-321
2. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602
3. Kessler RC, Aguilar-Gaxiola S, Andrade L, et al. Cross-national comparisons of comorbidities between substance use disorders and mental disorders: results from the International Consortium in Psychiatric Epidemiology. In: Bukoski WJ, Sloboda Z, eds. Handbook for Drug Abuse Prevention: Theory, Science, and Practice. New York, NY: Plenum Publishers; 2003
4. Pirkola SP, Isometsa E, Suvisaari J, et al. DSM-IV mood-, anxiety- and alcohol use disorders and their comorbidity in the Finnish general population: results from the Health 2000 Study. Soc Psychiatry Psychiatr Epidemiol 2005;40:1-10
5. Oslin DW, O'Brien CP, Katz IR. The disabling nature of comorbid depression among older DUI recipients. Am J Addict 1999;8:128-135
6. Thase ME, Salloum IM, Cornelius JD. Comorbid alcoholism and depression: treatment issues. J Clin Psychiatry 2001;62(suppl 20):32-41
7. Pirkola SP, Suominen K, Isometsa ET. Suicide in alcohol-dependent individuals: epidemiology and management. CNS Drugs 2004;18:423-436
8. Sher L, Oquendo MA, Galfalvy HC, et al. The relationship of aggression to suicidal behavior in depressed patients with a history of alcoholism. Addict Behav 2005;30:1144-1153
9. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004;291:1887-1896
10. Yoon SJ, Pae CU, Kim DJ, et al. Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1196-1201
11. Kranzler HR, Mueller T, Cornelius J, et al. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2006;26:13-20
12. Moak DH, Anton RF, Latham PK, et al. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol 2003;23:553-562
13. Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54:700-705
14. Cornelius JR, Salloum IM, Haskett RF, et al. Fluoxetine versus placebo in depressed alcoholics: a 1-year follow-up study. Addict Behav 2000;25:307-310
15. Roy A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry 1998;44:633-637
16. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292:338-343
17. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006;63:1358-1367
18. Pollock BG. Citalopram: a comprehensive review. Expert Opin Pharmacother 2001;2:681-698
19. Sanchez C, Bogeso KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004;174:163-176
20. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50:345-350
21. Krystal JH, Petrakis IL, Limoncelli D, et al. Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacology 2003;28:2020-2028
22. Sanacora G, Rothman DL, Mason G, et al. Clinical studies implementing glutamate neurotransmission in mood disorders. Ann N Y Acad Sci 2003;1003:292-308
23. Sanacora G, Gueorguieva R, Epperson CN, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004;61:705-713
24. Zarate CA Jr, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004;161:171-174
25. Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007;61:822-825
26. Kugaya A, Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 2005;10:808-819
27. Hurley SC. Lamotrigine update and its use in mood disorders. Ann Pharmacother 2002;36:860-873
28. McElroy SL, Zarate CA, Cookson J, et al. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry 2004;65:204-210
29. Krystal JH, Petrakis IL, Webb E, et al. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry 1998;55:354-360
30. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-864
31. Gortelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome: a double-blind placebo-controlled study. Arzneimittelforschung 1992;42:904-913
32. Zarate CA Jr, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006;163:153-155
33. Beck AT, Steer RA, Brown GK. BDI-II, Beck Depression Inventory: Manual. 2nd ed. San Antonio, Tex: Psychological Corp. Harcourt Brace; 1996
34. First MB, Spitzer RL, Williams JBW, et al. Structured Clinical Interview for DSM-IV (SCID). Washington, DC: American Psychiatric Association; 1995
35. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
36. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
37. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
38. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992;149:1148-1156
39. Fillenbaum GG, Beekly D, Edland SD, et al. Consortium to Establish a Registry for Alzheimer's Disease: development, database structure, and selected findings. Top Health Inf Manage 1997;18:47-58
40. Parsons OA. Neurocognitive deficits in alcoholics and social drinkers: a continuum? Alcohol Clin Exp Res 1998;22:954-961
41. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-897
42. Scott J, Huskisson EC. Graphic representation of pain. Pain 1976;2:175-184
43. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons With Harmful Alcohol Consumption, 2. Addiction 1993;88:791-804
44. Mäkelä P, Saarnio P. A study on the mortality of alcoholics [in Finnish]. Alkoholipolitiikka 1997;62:344-349
45. Paelecke-Habermann Y, Pohl J, Leplow B. Attention and executive functions in remitted major depression patients. J Affect Disord 2005;89:125-135
46. Collie A, Shafiq-Antonacci R, Maruff P, et al. Norms and the effects of demographic variables on a neuropsychological battery for use in healthy ageing Australian populations. Aust N Z J Psychiatry 1999;33:568-575